Picture loading failed.

Pre-Made Isatuximab biosimilar, Whole mAb, Anti-CD38 Antibody: Anti-ADPRC1/ADPRC 1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Isatuximab, sold under the brand name Sarclisa, is a monoclonal antibody (mAb) medication for the treatment of multiple myeloma.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-279-1mg 1mg 3090
GMP-Bios-ab-279-10mg 10mg Inquiry
GMP-Bios-ab-279-100mg 100mg Inquiry
GMP-Bios-ab-279-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Isatuximab biosimilar, Whole mAb, Anti-CD38 Antibody: Anti-ADPRC1/ADPRC 1 therapeutic antibody
INN Name Isatuximab
TargetCD38
FormatWhole mAb
DerivationChimeric (Mouse/Human)
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI Structure4cmh:BC
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2014
Year Recommended2015
CompaniesImmunoGen;Huntsman Cancer Institute;Roche;Sanofi
Conditions ApprovedMultiple myeloma
Conditions ActiveAcute myeloid leukaemia;Precursor cell lymphoblastic leukaemia-lymphoma;Colorectal cancer;Diffuse large B cell lymphoma;Hodgkin's disease;Solid tumours;Urogenital cancer
Conditions DiscontinuedNon-small cell lung cancer;Prostrate cancer;T-cell lymphoma
Development Techna